The Insides Company, which is commercialising a novel chyme reinfusion therapy (CRT) device for treating intestinal failure, has gained interim reimbursement in France.
It is only the third medical device in the world to be covered under France’s ‘prise en charge transitoire’ (PECT)
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
